Heidelberg Pharma AG

Regulatory Filings • Aug 12, 2015

News Details

Ad-hoc | 12 August 2015 19:25

WILEX AG announces discontinuation of collaboration between its subsidiary Heidelberg Pharma and Roche

WILEX AG / Key word(s): Alliance/Change in Forecast

12.08.2015 19:25

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---

WILEX AG announces discontinuation of collaboration between its subsidiary
Heidelberg Pharma and Roche

Munich, 12 August 2015 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) was
informed today that Roche is discontinuing its partnership with the WILEX
subsidiary Heidelberg Pharma GmbH with respect to their collaboration in
the field of antibody-targeted amanitin conjugates (ATACs). The licence
agreement was signed in 2013 and expanded in October 2014.

Roche has recently increased the focus of its oncology research strategy on
cancer immunotherapies and deprioritised other internal and external
oncology research programmes accordingly. Affected by this deprioritisation
are the collaborative research efforts with Heidelberg Pharma, which in
recent years have progressed well, on schedule, and in a mutually
satisfactory manner.

Updated financial outlook for 2015

As a consequence of the termination of existing collaborative efforts to
develop and identify novel antibody-targeted amanitin conjugates (ATACs),
WILEX AG revised today its financial outlook for the current financial
year. Due to lower sales revenues WILEX's cash reach is reduced from the
end of the second quarter 2016 to the first quarter of 2016.

---

Information and Explaination of the Issuer to this News:

About WILEX and Heidelberg Pharma

WILEX AG is a biopharmaceutical company which has a ready for partnering
portfolio of antibody-based diagnostic and therapeutic Phase III product
candidates for the detection and targeted treatment of clear cell renal
cell carcinoma. Research and development focus on the operations of its
subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances
the development of the innovative platform technology for antibody drug
conjugates (ADC technology) and provides pre-clinical drug discovery and
development services. WILEX is listed at the Frankfurt Stock Exchange: ISIN
DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at
http://www.wilex.com/.

Contact IR/PR Support
WILEX AG MC Services AG
Sylvia Wimmer Katja Arnold (CIRO)
Corporate Communications Executive Director
Tel.: +49 (0)89-41 31 38-29 Tel.: +49-89-210 228-40
E-mail: investors[at]wilex.com Mobile: +49 160 9360 3022
Grillparzerstr. 18, 81675 Munich E-mail: katja.arnold[at]mc-services.eu

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will', 'should', 'future', 'potential' or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

12.08.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 18
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE000A11QVV0
WKN: A11QVV
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart

End of Announcement DGAP News-Service

---